RxDoctor Payments Data

Robert Buckingham, MD

Internal Medicine · Ojai, CANPI 1023147675

Payments from drug & device makers

$707in general payments, 2019–2025

Across 35 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$181
  • Johnson & Johnson$147
  • Novo Nordisk$64
  • Otsuka America Pharmaceutical, Inc.$49
  • Boehringer Ingelheim$46
  • Novartis$45
  • plus $175 from 8 others

What the payments were for

  • Food & beverage$707100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$707 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$440,027
Medicare patients
434
Services billed
3,507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate17$132,796
XareltoRivaroxaban351$131,512
EliquisApixaban328$116,184
JardianceEmpagliflozin236$109,684
RybelsusSemaglutide54$59,532
JanuviaSitagliptin Phosphate121$53,096
HizentraImmun Glob G(Igg)/Pro/Iga 0-5022$48,342
TrulicityDulaglutide59$48,094
FarxigaDapagliflozin Propanediol51$29,786
OzempicSemaglutide21$23,485
Breo ElliptaFluticasone/Vilanterol37$14,899
Pantoprazole Sodium194$12,332
Budesonide40$12,007
CreonLipase/Protease/Amylase11$11,632
Chlorpromazine Hcl12$11,614

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto, Invokana$147$137,686368 claims
Neurocrine Biosciences, Inc.Ingrezza$38$132,79617 claims
PfizerEliquis$33$116,184328 claims
Boehringer IngelheimJardiance$46$109,684236 claims
Novo NordiskRybelsus, Ozempic$64$83,01775 claims
Lilly USA, LLCTrulicity$20$48,09459 claims
AstraZenecaFarxiga$181$29,78651 claims
NovartisEntresto$45$10,34012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Ojai

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →